Cancer drugs that unleash a patient’s immune system to attack tumors have rapidly won accelerated approval from the Food and Drug Administration. These checkpoint inhibitors have also quickly gained acceptance from oncologists.

That’s the goal of fast-track approval granted by the Food and Drug Administration to Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda — to speed drugs to people who have not found success with other cancer therapies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • More false hope to shut people up and make money off of the insurance scam. The misery isn’t felt by the ones making the rules to stop pain relief for those who need it. That is, until it happens to them or someone they care about.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy